Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Earnings Call Summary
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.22M | 50.19M | 52.61M | 66.64M | 81.84M | 65.26M |
| Gross Profit | 25.00M | 21.48M | 23.86M | 24.04M | 39.37M | 37.42M |
| EBITDA | 11.47M | 11.16M | 7.68M | -2.18M | 27.39M | 20.04M |
| Net Income | 6.12M | 6.24M | 2.35M | -10.10M | 15.85M | 11.11M |
Balance Sheet | ||||||
| Total Assets | 82.43M | 81.75M | 80.85M | 89.29M | 115.12M | 101.27M |
| Cash, Cash Equivalents and Short-Term Investments | 16.62M | 13.01M | 6.02M | 11.58M | 20.34M | 21.91M |
| Total Debt | 1.12M | 1.32M | 4.10M | 1.55M | 2.63M | 1.58M |
| Total Liabilities | 9.55M | 8.53M | 12.63M | 14.77M | 20.38M | 23.07M |
| Stockholders Equity | 71.73M | 72.33M | 67.12M | 73.35M | 94.12M | 77.65M |
Cash Flow | ||||||
| Free Cash Flow | 9.47M | 11.41M | -664.00K | 3.86M | 4.59M | 11.16M |
| Operating Cash Flow | 10.71M | 13.66M | 6.31M | 9.69M | 10.24M | 13.81M |
| Investing Cash Flow | -1.84M | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M |
| Financing Cash Flow | -1.44M | -4.08M | -3.65M | -11.04M | -6.16M | -5.21M |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £115.62M | 19.26 | 8.71% | ― | -1.43% | 28.57% | |
| ― | £6.98M | 1,125.00 | 0.08% | ― | 87.72% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | £18.83M | -1.65 | -51.63% | ― | 31.78% | 10.27% | |
| ― | £45.37M | -1.84 | ― | ― | ― | ― | |
| ― | £41.08M | -12.70 | ― | ― | 1557.07% | 24.70% |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings plc has announced the purchase of 919,331 of its ordinary shares at an average price of 28 pence per share, which will be held in treasury. The company also extended its share buyback program to include additional purchases of up to £1.0 million. This move is part of a strategy to manage the company’s capital structure and potentially enhance shareholder value. The buyback includes shares acquired from Harwood as an investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable. Following the buyback, the total number of ordinary shares carrying voting rights is 445,518,745.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 929,169 ordinary shares at a weighted average price of 27.5269 pence per share, which will be held in treasury. This transaction includes a notable acquisition of shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ aggregate indirect interest remains stable. The buyback impacts the company’s total voting rights, now consisting of 446,438,076 shares, and reflects a strategic move to manage shareholder interests and market positioning.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 929,169 of its ordinary shares, which will be held in treasury. This move is part of a strategic effort to manage its share capital and maintain the indirect beneficial interest of Mr. Mills, a non-executive director, at a stable level. The transaction involved acquiring shares from Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The buyback reflects EKF’s ongoing commitment to optimizing shareholder value and maintaining a balanced shareholding structure.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £30.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 1,017,352 ordinary shares at a weighted average price of 28 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights in the company. The transaction involved acquiring shares from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, facilitated by Harwood, the investment manager.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.35 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the repurchase of 709,193 of its ordinary shares at a price of 28 pence per share, which will be held in treasury. This buyback is part of a strategic move to manage the company’s share capital and maintain shareholder value. The transaction includes the acquisition of shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ indirect beneficial interest remains stable and does not exceed 30% of the total voting rights. This move could impact the company’s market positioning by potentially increasing shareholder confidence and stabilizing the share price.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £32.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings’ recent earnings call conveyed a generally positive sentiment, highlighting notable revenue and profit growth, increased production capacity, and successful new contracts. Despite facing challenges in the APAC region and some market constraints affecting their share buyback program, the company remains optimistic. The positives, including significant production increases and strategic growth plans, appear to outweigh the negatives.
EKF Diagnostics Holdings plc has announced the implementation of a Long Term Incentive Plan (LTIP) for its senior executives, with a specific award granted to CEO Gavin Jones. The LTIP is designed to align executive performance with shareholder value creation, with vesting conditions based on the growth of Adjusted EBITDA per share over a three-year period. This move reflects the company’s commitment to incentivizing its leadership while potentially enhancing its market position and stakeholder confidence.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc reported record analyzer sales and improved earnings for the first half of 2025, with gross margins rising to 50.2% and a 16.1% increase in pre-tax profit. The company is on track to meet full-year revenue and adjusted EBITDA growth expectations, supported by strong performances in Hematology and β-HB product lines. The strategic development plan is yielding results, with increased production capacity and a focus on high-margin products driving profitability. The company also completed a share buyback and canceled a loan facility due to strong cash generation, indicating a robust financial position.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc will announce its interim results for the first half of 2025 on 16 September and will host a live online presentation for investors on the same day. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £31.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the signing of three new contracts in the Hematology point-of-care testing sector, valued at approximately €4.65 million. These contracts, secured by EKF’s distribution partners in Latin America and Africa, include a significant return to the Peruvian market and the company’s first sales in Uganda. To meet the rising demand, EKF plans to increase its production capacity by 30% at its Barleben site as part of its five-year strategic development plan. This expansion reinforces the company’s confidence in achieving its revenue and adjusted EBITDA targets for FY 2025, aligning with market expectations. The continued global expansion of EKF’s Hematology analyzer footprint is expected to drive future growth and higher margin revenue through consumable pull-through.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the signing of three new contracts in the Hematology point-of-care testing sector, valued at approximately €4.65 million. These contracts, secured by distribution partners in Latin America and Africa, mark significant sales growth in Peru and new market entry in Uganda. To meet rising demand, EKF is increasing its production capacity by 30% at its Barleben site as part of its five-year strategic development plan. This expansion is expected to drive revenue and adjusted EBITDA growth in line with market expectations, reinforcing the company’s confidence in its strategic focus on Hemoglobin testing as a key growth area.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc reported a stable revenue of £25.2 million for the first half of 2025, with improvements in gross margins and cash generation, aligning with management expectations. The company saw significant growth in its hematology and β-HB sectors, with revenues increasing by 8% and 12% respectively, and is optimistic about future contract manufacturing and fermentation opportunities, indicating a positive trajectory in its strategic development plan.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.